Publications by authors named "A D Vassilopoulos"
Infections in psoriatic arthritis: association with treatment.
Ther Adv Musculoskelet Dis
October 2024
Article Synopsis
- - Serious infections (SIs) are a major concern for patients with psoriatic arthritis (PsA), especially when treated with various medications, including traditional options like methotrexate and newer biologics such as IL-23 inhibitors and JAK inhibitors.
- - While the overall incidence of SIs in PsA patients is lower than that in rheumatoid arthritis patients, there are ongoing safety concerns, particularly with the potential reactivation of latent infections like tuberculosis when using TNF inhibitors, which can be managed with proper screening.
- - Newer treatments like IL-23 inhibitors show no increase in common infection risk, but JAK inhibitors are associated with an elevated risk of herpes zoster, highlighting the importance of monitoring and preventive measures in treatment
Patients with rheumatoid arthritis (RA) who receive immunosuppressive medications have a heightened risk of infection. The goal of our study was to calculate the pooled cumulative incidence and risk of infection in patients with RA treated with Janus kinase inhibitors (JAKi). The PubMed and EMBASE databases were queried for randomized controlled trials comparing patients with RA treated with JAKi (upadacitinib, baricitinib, tofacitinib, peficitinib, or filgotinib), defined as the treatment group, compared with control subjects, defined as participants receiving placebo or treatment regimen that was similar to that of participants in the treatment group, with the exception of JAKi.
View Article and Find Full Text PDFBackground: Early in the pandemic, extensive attention was cast on limited inclusion of historically underrepresented patient populations in COVID-19 clinical trials. How diverse representation improved following these initial reports remains unclear.
Methods: PubMed, Embase and the Cochrane Library were searched (through April 2024) for US-based COVID-19 trials.
Background: Patients with inflammatory bowel disease (IBD) are at increased risk of infection. The aim of this study was to assess the cumulative incidence and risk of infection in patients with IBD treated with interleukin (IL)-targeting agents.
Methods: We searched PubMed, EMBASE, and Web of Science for randomized controlled trials including patients with IBD receiving IL-targeting agents compared with patients receiving placebo or treatment that only differed from the intervention arm in the absence of an IL-targeting agent.
Background: Understanding why some triple-negative breast cancer (TNBC) patients respond poorly to existing therapies while others respond well remains a challenge. This study aims to understand the potential underlying mechanisms distinguishing early-stage TNBC tumors that respond to clinical intervention from non-responders, as well as to identify clinically viable therapeutic strategies, specifically for TNBC patients who may not benefit from existing therapies.
Methods: We conducted retrospective bioinformatics analysis of historical gene expression datasets to identify a group of genes whose expression levels in early-stage tumors predict poor clinical outcomes in TNBC.